- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Biocure Technology
Building Biopharmaceutical Solutions And Developing Biosimilar Products
Overview
Biocure Technology Inc. (CSE:CURE, OTC:BICTF) is a Korean biopharmaceutical technology company currently using their proprietary technology platform to develop biosimilar products. In parallel, the company is also making use of this same technology to test a CAR-T cell targeted immune-therapy designed to treat terminal leukemia patients.
Using its proprietary genetic engineering technology platform, Biocure has designed a suite of exclusive processes aimed at developing biosimilars, defined as biological products highly similar to FDA-approved reference products originally developed by another organization. Once patents for a given product are expired, companies, like Biocure, are able to use their own processes to design and deploy almost identical products, that meet strict FDA specifications. A relatively underpopulated market, Biocure has found an opportunity in creating biosimilars like its Interferon beta-1b, used to treat multiple sclerosis (MS) symptoms.
Alongside its biosimilar products, Biocure has also been working towards being the third worldwide developer of a CAR-T cell therapy, an innovative approach to treating relapse and refractory cancers. Biocure’s therapy is designed to address latter-stage acute lymphoblastic leukemia. Preclinical trial results displayed a complete remission of cancerous cells within seven to 28 days from the injection, with no toxicity symptoms. The results meet Korean FDA guidelines and allow Biocure to advance towards clinical trials.
Biocure has also partnered with Y Biologics to develop a combined anticancer therapy that utilizes its CAR-T cell therapy. The two companies also intend to develop a next generation anticancer treatment for solid tumors pending preclinical trial results.
Company Highlights
- Playing key role in underpopulated biosimilar market
- Interferon beta-1b to be one of a few biosimilar products for MS in multi-billion-dollar market
- CAR-T therapy designed to treat acute lymphoblastic leukemia
- Preclinical results displayed complete remission of cancerous cells within seven to 28 days with no toxicity
- Collaborative partnership in place with Y Biologics to develop combined anticancer therapy
- Strong relationships with universities and researchers, as well as Korea’s FDA body
- Joint venture partnership in place with MHU and Gold Dream
- Management team with over 95 years of collective experience
Interactive Chart
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.